Pedro Nazareth Aguiar

1.4k total citations
73 papers, 861 citations indexed

About

Pedro Nazareth Aguiar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Pedro Nazareth Aguiar has authored 73 papers receiving a total of 861 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 16 papers in Economics and Econometrics. Recurrent topics in Pedro Nazareth Aguiar's work include Cancer Immunotherapy and Biomarkers (22 papers), Lung Cancer Treatments and Mutations (17 papers) and Economic and Financial Impacts of Cancer (15 papers). Pedro Nazareth Aguiar is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Lung Cancer Treatments and Mutations (17 papers) and Economic and Financial Impacts of Cancer (15 papers). Pedro Nazareth Aguiar collaborates with scholars based in Brazil, United States and Portugal. Pedro Nazareth Aguiar's co-authors include Gilberto Lopes, Hakaru Tadokoro, Ramon Andrade de Mello, Benjamin Haaland, Auro del Giglio, Pui San Tan, Peter Hall, Ilka Lopes Santoro, Giannis Mountzios and Pedro F. Oliveira and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Pedro Nazareth Aguiar

68 papers receiving 853 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pedro Nazareth Aguiar Brazil 13 584 428 122 120 98 73 861
Chana Weinstock United States 12 558 1.0× 301 0.7× 106 0.9× 119 1.0× 127 1.3× 44 842
Timothée Olivier Switzerland 15 463 0.8× 341 0.8× 65 0.5× 119 1.0× 123 1.3× 83 873
Sirisha L. Mushti United States 11 697 1.2× 312 0.7× 218 1.8× 135 1.1× 150 1.5× 16 927
Huabin Hu China 14 491 0.8× 203 0.5× 95 0.8× 88 0.7× 156 1.6× 68 751
Yada Kanjanapan Australia 12 583 1.0× 273 0.6× 154 1.3× 108 0.9× 100 1.0× 31 802
Meredith K. Chuk United States 14 429 0.7× 260 0.6× 133 1.1× 116 1.0× 175 1.8× 29 858
Anastasios Dimou United States 16 481 0.8× 311 0.7× 56 0.5× 115 1.0× 201 2.1× 67 800
A. Misino Italy 11 755 1.3× 368 0.9× 64 0.5× 134 1.1× 134 1.4× 25 983
Meghan Shea United States 13 449 0.8× 373 0.9× 48 0.4× 94 0.8× 125 1.3× 32 777
Concetta Elisa Onesti Italy 16 465 0.8× 287 0.7× 109 0.9× 255 2.1× 334 3.4× 58 937

Countries citing papers authored by Pedro Nazareth Aguiar

Since Specialization
Citations

This map shows the geographic impact of Pedro Nazareth Aguiar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro Nazareth Aguiar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro Nazareth Aguiar more than expected).

Fields of papers citing papers by Pedro Nazareth Aguiar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedro Nazareth Aguiar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro Nazareth Aguiar. The network helps show where Pedro Nazareth Aguiar may publish in the future.

Co-authorship network of co-authors of Pedro Nazareth Aguiar

This figure shows the co-authorship network connecting the top 25 collaborators of Pedro Nazareth Aguiar. A scholar is included among the top collaborators of Pedro Nazareth Aguiar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedro Nazareth Aguiar. Pedro Nazareth Aguiar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fabre, Bibiana, et al.. (2024). Evaluating GPT-4 as an academic support tool for clinicians: a comparative analysis of case records from the literature. SHILAP Revista de lepidopterología. 4. 100042–100042. 2 indexed citations
2.
Aguiar, Pedro Nazareth, et al.. (2024). Natural supplementation to effectively treat cancer-induced fatigue: evidence of a meta-analysis on the use of guaraná. Revista da Associação Médica Brasileira. 70(10). e20240528–e20240528.
3.
4.
Aguiar, Pedro Nazareth, et al.. (2023). Physical Examination in Medical Oncology Guiding the Development of a Protocol for Teleoncology Care in a Public Health Care Oncology Service. JCO Clinical Cancer Informatics. 7(7). e2200152–e2200152. 2 indexed citations
5.
Aguiar, Pedro Nazareth, et al.. (2023). P2.28-01 Lung Cancer Mortality in Brazil: Temporal Trends, Regional Disparities and the Impact of the COVID-19 Pandemic. Journal of Thoracic Oncology. 18(11). S402–S403.
6.
Aguiar, Pedro Nazareth, et al.. (2023). Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access. Expert Review of Pharmacoeconomics & Outcomes Research. 23(9). 981–987. 1 indexed citations
7.
Aguiar, Pedro Nazareth, et al.. (2023). Challenges and Opportunities in Building a Health Economic Framework for Personalized Medicine in Oncology. Personalized Medicine. 20(5). 453–460. 1 indexed citations
8.
Aguiar, Pedro Nazareth, et al.. (2022). Predictive Genetic Biomarkers in Immune Checkpoint Inhibitors for non-small-cell Lung Cancer. Immunotherapy. 14(4). 249–257. 3 indexed citations
9.
Araujo, Luiz H., et al.. (2021). Patient-Centered Outcomes in Non-Small-Cell Lung Cancer: A Real-World Perspective. Future Oncology. 17(14). 1721–1733. 4 indexed citations
10.
Aguiar, Pedro Nazareth, Felipe Roitberg, Gilberto Lopes, & Auro del Giglio. (2020). Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System. Jornal Brasileiro de Pneumologia. 46(4). e20180255–e20180255. 1 indexed citations
11.
12.
Aguiar, Pedro Nazareth, et al.. (2019). In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments. Value in Health Regional Issues. 20. 47–50. 15 indexed citations
13.
Adashek, Jacob J., Pedro Nazareth Aguiar, Natalie Galanina, & Razelle Kurzrock. (2019). Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. Journal for ImmunoTherapy of Cancer. 7(1). 130–130. 7 indexed citations
14.
Aguiar, Pedro Nazareth, Benjamin Haaland, Wungki Park, et al.. (2018). Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer. JAMA Oncology. 4(8). 1080–1080. 97 indexed citations
15.
Aguiar, Pedro Nazareth, et al.. (2017). OA17.01 Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US. Journal of Thoracic Oncology. 12(1). S308–S308. 1 indexed citations
16.
Aguiar, Pedro Nazareth, et al.. (2017). P2.07-054 Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(11). S2149–S2150. 1 indexed citations
17.
Aguiar, Pedro Nazareth, Ramon Andrade de Mello, Hakaru Tadokoro, & Gilberto Lopes. (2017). Economic impact of immune checkpoint inhibitor therapy in Brazil and strategies to improve access.. Journal of Clinical Oncology. 35(15_suppl). 6612–6612. 1 indexed citations
18.
Aguiar, Pedro Nazareth, et al.. (2016). Chemotherapy for elderly patients with gastric cancer: experience of a brazilian center. SHILAP Revista de lepidopterología. 10(2). 71–79.
19.
Mello, Ramon Andrade de, et al.. (2016). EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer. Recent Patents on Anti-Cancer Drug Discovery. 11(4). 393–400. 8 indexed citations
20.
Aguiar, Pedro Nazareth, Hakaru Tadokoro, Nora Manoukian Forones, et al.. (2016). Current Advances in Targeted Therapies for Metastatic Gastric Cancer: Improving Patient Care. Future Oncology. 12(6). 839–854. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chana Weinstock Breakdown of academic impact, for papers by Timothée Olivier Breakdown of academic impact, for papers by Sirisha L. Mushti Breakdown of academic impact, for papers by Huabin Hu Breakdown of academic impact, for papers by Yada Kanjanapan Breakdown of academic impact, for papers by Meredith K. Chuk Breakdown of academic impact, for papers by Anastasios Dimou Breakdown of academic impact, for papers by A. Misino Breakdown of academic impact, for papers by Meghan Shea Breakdown of academic impact, for papers by Concetta Elisa Onesti
Rankless by CCL
2026